drugset / Trial / NCT00408330

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

NCT00408330

Phase 2 Completed 48 enrolled LEO Pharma Bayer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

Timeline

Start
2006-12
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelaic acid Small molecule 15 % Topical

Indications